4//SEC Filing
BERNS PAUL L 4
Accession 0000950170-25-079920
CIK 0001885522other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:30 PM ET
Size
21.7 KB
Accession
0000950170-25-079920
Insider Transaction Report
Form 4
BERNS PAUL L
DirectorSee Remarks
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−955,864→ 0 totalExercise: $1.69Exp: 2033-06-28→ Common Stock (955,864 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−342,500→ 0 totalExercise: $1.69Exp: 2034-02-14→ Common Stock (342,500 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+497,049→ 497,049 totalExercise: $0.72Exp: 2032-01-27→ Common Stock (497,049 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+342,500→ 342,500 totalExercise: $0.72Exp: 2034-02-14→ Common Stock (342,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−497,049→ 0 totalExercise: $1.69Exp: 2032-01-27→ Common Stock (497,049 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−2,000,000→ 0 totalExercise: $1.69Exp: 2035-02-13→ Common Stock (2,000,000 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+955,864→ 955,864 totalExercise: $0.72Exp: 2033-06-28→ Common Stock (955,864 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+2,000,000→ 2,000,000 totalExercise: $0.72Exp: 2035-02-13→ Common Stock (2,000,000 underlying)
Footnotes (6)
- [F1]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.
- [F3]25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F4]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F5]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F6]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001202769
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:30 PM ET
- Size
- 21.7 KB